| Entry |
|
|---|
| Name |
Crisaborole (USAN/INN);
Eucrisa (TN) |
|---|
| Product |
|
|---|
| Formula |
C14H10BNO3
|
|---|
| Exact mass |
251.0754
|
|---|
| Mol weight |
251.0451
|
|---|
| Structure |
|
|---|
| Remark |
|
|---|
| Efficacy |
Antipsoriatic, Phosphodiesterase inhibitor |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D11 OTHER DERMATOLOGICAL PREPARATIONS
D11A OTHER DERMATOLOGICAL PREPARATIONS
D11AH Agents for dermatitis, excluding corticosteroids
D11AH06 Crisaborole
D10873 Crisaborole (USAN/INN) <US>
USP drug classification [BR:br08302]
Dermatological Agents
Dermatitis and Pruitus Agents
Dermatitis and Pruitus Agents, Other
Crisaborole
D10873 Crisaborole (USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE4
D10873 Crisaborole (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10873
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10873
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10873
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 19
1 C8x C 16.9311 -16.0216
2 C8y C 16.9311 -17.4208
3 C8x C 18.1205 -18.1205
4 C8y C 19.3798 -17.4208
5 C8y C 19.3798 -16.0216
6 C8x C 18.1205 -15.3219
7 O2a O 15.7417 -18.1205
8 C1x C 20.7091 -17.8406
9 O2x O 21.5487 -16.7212
10 Z B 20.7091 -15.6018
11 O1a O 21.1289 -14.2725
12 C8y C 14.5340 -17.4362
13 C8x C 14.5924 -16.0305
14 C8x C 13.3043 -15.3405
15 C8y C 12.0976 -16.0505
16 C8x C 12.1092 -17.4562
17 C8x C 13.3273 -18.1462
18 C3b C 10.8803 -15.3609
19 N3a N 9.6678 -14.6609
BOND 21
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 2 7 1
8 4 8 1
9 8 9 1
10 9 10 1
11 5 10 1
12 10 11 1
13 7 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 15 18 1
21 18 19 3
|
|---|
